Bevacizumab in advanced cancer, too much or too little?

@article{Jirillo2008BevacizumabIA,
  title={Bevacizumab in advanced cancer, too much or too little?},
  author={Antonio Jirillo and Federica Vascon and M Giacobbo},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2008},
  volume={19 10},
  pages={1817-8}
}
Last year Bernardi et al. [1] said ‘By 2008, anticancer drugs will be the leading therapeutic area in term of sales. This appraisal has been done by the Intercontinental Marketing Services (IMS) Health, a provider of business intelligence and strategic consulting services for the pharmaceutical and ‘health care’ industries. Oncology, considered a niche sector just a few years ago, will reach a business volume of 41 billion dollars in 2008 compared with 24 billion dollars in 2004. The economic… CONTINUE READING

References

Publications referenced by this paper.

Allocation of public sources in oncology: which role can ethics play?

Annals of oncology : official journal of the European Society for Medical Oncology • 2007
View 2 Excerpts

Similar Papers

Loading similar papers…